Jim Cramer Rejects UiPath Despite Cheap Valuation, Backs Affirm
Cramer called UiPath cheap but lacking catalysts, endorsed Karman and Affirm, warned on Onto and Nio, and favored Regeneron, Vertex and Amgen over Alnylam
Follow the latest Vertex Pharmaceuticals Inc. (VRTX) news and market headlines alongside the live VRTX price. Stay informed on what's moving VRTX.
Cramer called UiPath cheap but lacking catalysts, endorsed Karman and Affirm, warned on Onto and Nio, and favored Regeneron, Vertex and Amgen over Alnylam
Vertex Pharmaceuticals and Regeneron Pharmaceuticals are recommended as strong growth stocks for November. Both biotech companies started 2026 slowly but have rebounded with above-average returns. Vertex is poised for approval of povetacicept for kidney disease and has a pipeline potentially worth $10 billion in annual sales. Regeneron is driven by blockbuster Dupixent sales (up 35% YoY) and is managing Eylea's decline with a newer HD formulation.
The article compares Johnson & Johnson and Vertex Pharmaceuticals as investment options for 2027. JNJ is a diversified healthcare giant with $99.3B in revenue and strong cash flow, while VRTX is a specialized biotech leader with $13B in revenue focused on cystic fibrosis and expanding into gene therapies. Despite VRTX's higher growth rate and lower P/E ratio, JNJ is recommended as the better buy due to its superior valuation multiples (P/E 25.4x vs 29.6x, P/S 6.8x vs 10.5x) and established market position.
Natera Inc. (NASDAQ:NTRA) short sellers added to their positions as of the latest settlement date.Short interest rose 3.77% to 6.07 million shares as of the Oct. 30 settlement date, from 5.85 million at the Oct. 15
The global biotechnology market, valued at USD 2.02 trillion in 2026, is projected to reach USD 6.34 trillion by 2035 at a 13.61% CAGR. Leading biotech companies including Amgen, Gilead, Regeneron, Vertex, and Moderna reported strong Q3 2026 results with revenue growth ranging from 8% to 36%. The sector experienced record dealmaking activity with major acquisitions totaling tens of billions of dollars, driven by patent expiries, strong cash flows, and strategic pipeline expansion in oncology, immunology, and advanced therapies.
The article compares two healthcare ETFs: State Street's XPH (Pharmaceuticals) and iShares' IBB (Biotechnology). XPH charges lower fees (0.35% vs 0.44%), offers higher dividend yield (0.4% vs 0.2%), and focuses on smaller pharmaceutical companies that are acquisition targets. IBB is significantly larger with $11.3B in assets under management and holds 243 established biotech firms. The analyst recommends XPH for long-term investors due to the pharmaceutical industry's active M&A activity and smaller companies' takeover potential.
The article compares Amgen and Vertex Pharmaceuticals as investment options for 2027. Amgen offers diversified revenue streams across multiple drug franchises with lower valuation metrics but faces biosimilar competition and pricing pressures. Vertex demonstrates faster growth driven by cystic fibrosis dominance and promising pipeline candidates like Povetacicept, though at a premium valuation. The analyst recommends Vertex for long-term growth investors despite higher valuations, citing its superior growth trajectory and innovative pipeline.
Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 10 years by 6.32% on an annualized basis producing an average annual return of 19.42%. Currently, Vertex Pharmaceuticals has a market
Vertex Pharmaceuticals has been heavily searched on Zacks.com and has outperformed the broader market with a +12.9% return over the past month. However, the company faces headwinds with declining earnings estimates and a Zacks Rank #3 (Hold) rating, suggesting it may perform in line with the market. The stock is trading at a premium valuation (Grade D) relative to peers, with mixed earnings surprise history.
Vertex released its 2026 CompOps Index showing that enterprises with indirect tax as a standing board item are four times less likely to have errors identified externally and nearly twice as likely to respond to tax-authority notices within five business days. Only 16% of enterprises currently have indirect tax as a standing board item, while 43% only discuss it when problems arise. The study also found that enterprises with board-level tax discussions are more likely to deploy AI autonomously in tax workflows (54% vs. 21%) and maintain better regulatory compliance.
News and data on this page is provided by our partnered third-party news and market data provider, with the original publisher credited on each article. All third-party content reflects the views of the original publisher and does not represent the views of MEXC. Price and market data shown on this page are provided by third-party data providers and may be delayed. MEXC offers trading products related to VRTX, including RealStocks and Stock Futures.
The content on this page is provided for informational purposes only and does not constitute investment, financial, or trading advice. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of any news or market data shown. Trading U.S. stocks and related products involves significant risk, and prices can move sharply in a short period. Past performance does not guarantee future results. Please conduct your own research and assess your financial situation and risk tolerance before making any investment decisions. MEXC is not liable for any losses arising from the use of this information.